Testing a new imaging agent for Parkinson's and related conditions
Part of Brain & nervous system clinical trials.
This study tests an investigational imaging agent called SST001, which may help doctors see a protein linked to Parkinson's disease (PD) and multiple system atrophy (MSA) in the body. It will be given to healthy volunteers and patients with PD or MSA to check safety, how it spreads, and how the body handles it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of Parkinson's disease or multiple system atrophy (or you are a healthy volunteer).
- If you are on Parkinson's or MSA treatment, your dose has been stable for at least 4 weeks.
- You are willing to follow study procedures, including imaging tests like PET/CT or MRI.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if applicable.
- No history of other serious neurological disorders, active infections (like hepatitis or HIV), or drug/alcohol abuse in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects data from people with Parkinson's disease or multiple system atrophy (MSA) to better understand these conditions. You will have blood, saliva, optional spinal fluid tests, and brain scans (MRI, PET/SPECT).
This trial uses a new imaging agent (like a dye) to see signs of Parkinson's disease in the brain. If you have Parkinson's or a related condition like Lewy body dementia or multiple system atrophy, this scan may help researchers better understand these illnesses.
This research study tests a new type of brain scan (called a PET scan) that may help detect early signs of Parkinson's disease and similar conditions. You'll receive the scan and may have a spinal tap to check for specific protein markers.
This phase 3 trial tests a new oral drug (MSA-01) for people with multiple system atrophy. It aims to see if the drug can slow disease progression and improve daily function.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
This early-stage research trial tests a new brain-imaging tracer called [11C]MODAG-005 to help doctors better understand Parkinson's disease (PD) and multiple system atrophy (MSA). You would undergo PET/CT and MRI scans twice, a few weeks apart, to see how reliable the imaging is.
Hear when a new Multiple System Atrophy (MSA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.